Skip to main content


Company Overview

Company Profile

Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs). These targeted immunotherapies offer the unique opportunity to create “single molecule cocktails” comprised of targeted small molecules and peptides coupled to a human antibody fragment (Fc). DFCs are designed to save lives and improve the standard of care for patients facing serious diseases by inhibiting specific disease targets while simultaneously engaging the immune system. Cidara is headquartered in San Diego, California.

Contact Us

Investor Contact
Brian Ritchie
LifeSci Advisors
(212) 915-2578

Media Contact
Michael Fitzhugh
LifeSci Communications

Stock Quote